Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.34 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.34 |
| ▸ | STK4 | Q13043 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7552485 | 1.00 | ALDH1A1 (0.35) | ALDH1A1CYP2D6OPRM1OPRD1STK4 | |
| SCHEMBL13054258 | 0.88 | BACE1 (0.35) | ALDH1A1KMT2A | |
| SCHEMBL7548240 | 0.88 | BACE1 (0.35) | ALDH1A1KMT2A | |
| SCHEMBL7548572 | 0.88 | ALDH1A1 (0.40) | ALDH1A1CYP2D6KMT2A | |
| SCHEMBL13054359 | 0.88 | ALDH1A1 (0.40) | ALDH1A1CYP2D6KMT2A | |
| SCHEMBL14105600 | 0.88 | OPRD1 (0.34) | ALDH1A1CYP2D6OPRM1OPRD1KMT2A | |
| SCHEMBL14106069 | 0.88 | STK4 (0.33) | CYP2D6OPRM1OPRD1STK4 | |
| SCHEMBL13081542 | 0.88 | STK4 (0.38) | OPRM1STK4 | |
| SCHEMBL7583944 | 0.87 | OPRD1 (0.37) | CYP2D6OPRM1OPRD1CA12CA1 | |
| SCHEMBL7555608 | 0.87 | CCR1 (0.36) | OPRM1STK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100292203-A1 | HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS | SCHERING CORPORATION | 2010-11-18 | — | — | US | disclosed |
| WO-2008103351-A2 | HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS | SCHERING CORPORATION (US) | 2008-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292203-A1 | HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS | CHRM1, CHRM2, PRSS1 | ALDH1A1 4505/4885CYP2D6 959/4885OPRM1 226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.